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SKIN-TO-SKIN INTERVENTIONS IN INFANTS WITH NEONATAL 
ABSTINENCE SYNDROME 
GAZAL ARORA 
ABSTRACT 
Background 
The prevalence of neonatal abstinence syndrome (NAS) is on the rise in the United 
States, as the epidemic of opioid misuse continues1. Several infants with in utero 
exposure to opioids are born with NAS, and exhibit symptoms of withdrawal and 
dependence upon birth when the maternal source of opioid is discontinued2. Due to the 
novelty of the syndrome, there are several knowledge gaps in current literature that 
remain to be explored.  
 
Literature Review 
The exact mechanism of development of NAS in infants remains unknown, yet the 
clinical symptomatology and results of a few recent studies suggest that there is an 
association with NAS severity and dysregulation of autonomic nervous system (ANS) 
functioning in these infants3. In recent years, pharmacological treatments for these infants 
have become standardized4. However, non-pharmacological treatments have been 
adopted from treatment guidelines of other high-risk infant populations and their efficacy 
warrants further evaluation in infants with NAS. Kangaroo care (KC) is a supportive 
therapy commonly applied to many high-risk infant populations because of its 
physiologically stabilizing effects5. The therapy has been demonstrated to be especially 
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beneficial in the treatment of preterm infants, a population that similarly requires 
additional maturation of their ANS upon birth,6. Neurobehavioral theories suggest ANS 
functioning in infancy is a strong predictor of long-term social, behavioral, and cognitive 
development outcomes7,8.  
 
Proposed project 
This prospective cohort study is designed to provide pilot data to establish if KC can be 
utilized to mature ANS maturation in infants with NAS.  
 
Conclusions and significance 
KC is an inexpensive, readily available, low risk intervention that could improve 
neurobehavioral outcomes in infants with NAS. The results of this study could reduce 
clinical symptoms, potentiate long-term behavior outcomes, and better define treatment 
practices for infants with NAS by facilitating a targeted intervention to improve 
outcomes.   
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INTRODUCTION 
Background 
The current opioid epidemic in the United States represents a major public health 
problem. In recent years, providers are prescribing even more opioids, contributing to the 
increased dependence and abuse of these substances1. Although the prevalence is 
increasing in the general population, women in their child rearing years are particularly 
vulnerable due to potential obstetric complications2. An opioid substitution program, 
primarily treatment with methadone, remains the gold standard of treatment for women 
with opioid dependence during pregnancy9. The methadone treatment has been shown to 
have successful pregnancy outcomes, however can have critical consequences to the 
infant. In-utero exposure to opioids results in 60-90% of infants experiencing drug 
withdrawal symptoms upon birth, known NAS10. Infants born with NAS face many early 
life obstacles, most evident in their clinical withdrawal symptoms11.  
Many infants born with NAS require pharmacological treatment that results in an 
extended hospital stays that usually range from 8-60 days1. Although most clinical 
practice guidelines focus on pharmacological treatment of NAS, non-pharmacological 
interventions are first line in treatment and crucial to recovery. These non-
pharmacological interventions include breastfeeding, non-nutritive suckling practices 
while being held by the mother, swaddling, and rocking.12  
Since little empirical literature currently exists regarding non-pharmacological 
treatments for NAS, several of the treatment strategies for NAS have been adapted from 
standards set in the literature for treatment for preterm infants in the neonatal intensive 
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care unit (NICU). Preterm infants are a high-risk population of infants that share several 
similar vulnerabilities and early life obstacles as infants with NAS. These similarities 
include immature physiological development, extended hospital stays, additional 
requirements of extensive medical care, and limited direct contact with mother following 
birth6.  
The pathophysiology of NAS is complex and not yet entirely understood, 
however recent studies have shown that infants experiencing NAS display difficulty 
regulating their ANS14. Neurobehavioral research suggests that ANS functioning in 
infancy is a strong predictor of later behavioral and attachment outcomes7. Current NAS 
treatment guidelines focus on alleviating acute clinical symptoms in these infants, but 
treatment regimens have not yet expanded into modifying ANS regulation in these infants 
permanently. Subsequently, the long-term developmental implications of NAS in these 
infants remain unexplored.  
This study proposes that non-pharmacological interventions, specifically KC, can 
be used in the NAS population to promote the maturation of the ANS in these infants. 
Modification of the ability to regulate behavioral and physiological responses will allow 
these infants to have improved developmental outcomes7.  
Statement of the Problem 
Combinations of pharmacological and non-pharmacological treatments are implemented 
in the management of infants with NAS. Pharmacological treatments for withdrawal 
symptoms have been extensively studied and standardized. Conversely, there remains 
paucity in current literature examining the efficacy of non-pharmacological treatments in 
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the NAS population despite their use as first-line therapies in these infants. For this 
reason, further research regarding efficacy of non-pharmacological treatments is 
warranted.  
Skin-to-skin interventions, such as KC, are therapeutic options that have been 
beneficial in the treatment of other high-risk infant populations, specifically preterm 
infants. An important feature of these sensory interventions is that they stimulate the 
vagus nerve, which in turn enhances the ANS. Dysregulation of the ANS is an underlying 
mechanism in NAS. Implementing interventions that directly modify this mechanism 
could have lifelong implications, since the ability to regulate the ANS in infancy is a 
predictor of future behavioral outcomes8.  
Hypothesis 
Skin-to-skin interventions, such as KC, will enhance levels of vagal tone by decreasing 
heart rate (HR) and increasing heart rate variability (HRV) in infants with NAS.  
Objectives and Specific Aims 
The American Academy of Pediatrics (AAP) provides national guidelines for the care of 
NAS. Although pharmacological treatments have been standardized, non-
pharmacological treatments remain unspecific. 15 This study aims to first, determine the 
baseline ANS function in infants with NAS during the first few weeks of life, and second, 
establish if KC can serve as an intervention that facilitates maturation of this baseline 
function.  
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The specific objectives of this study are: 
1. To determine the baseline trajectory of ANS maturation in infants with NAS 
using measures of HR and HRV during quiet sleep 
2. To demonstrate that infants with NAS who receive skin-to-skin intervention of 
KC exhibit improved physiological responses (i.e. decreased HR, increased HRV) 
compared to infants with NAS who do not receive the intervention 
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REVIEW OF THE LITERATURE 
Overview  
 
Definition of NAS and clinical presentation  
 
NAS is a constellation of clinical symptoms that develop in an infant with intrauterine 
exposure to opioids or other drugs during pregnancy. NAS is a complex condition, with 
significant variability in presentation. Symptoms include hyperirritability, autonomic 
dysfunction, gastrointestinal complications, sleep-wake period disturbances, tremors, 
fever, high-pitched cry, increased muscle tone, and uncoordinated sucking and 
swallowing reflexes11. The onset of symptoms begins within 24-48 hours after birth, and 
can last from 8-60 days1. The modified Finnegan scoring system assesses clinical 
symptoms and is used to quantify NAS severity and determine pharmacological 
management2. Figure 1 shows the algorithm of treatment management.  
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Figure 1. Algorithm for treatment management of NAS in infants9
 
Epidemiology of NAS 
 
Opioids have been used as analgesics since ancient civilizations. Addiction became 
prevalent after the advent of morphine in 1804 and heroin in 18742. Although withdrawal 
from discontinuing opioids was common in adult opioid abusers, it was not until 1875 
that withdrawal symptoms were noted in an infant and the presentation was termed 
congenital morphinism2. Most infants suffering from withdrawal at birth died soon after2.  
In 1947, the first infant with NAS was treated successfully with morphine 
administration2. Methadone became the gold standard of treatment for opioid abuse in 
19649. Although methadone is associated with withdrawal symptoms, it remains the 
standard care for women with opioid dependence during pregnancy.  
The incidence of NAS has increased significantly over the last two decades. The 
CDC reports from the years 2000 to 2012 state that the incidences of NAS increased by 
383% in USA4. Although other substances, such as cocaine and sedatives, have been 
	  7 
found to result in NAS, the condition is most often attributed to utero opioid exposure. 
This opioid exposure is most often seen in the settings of medication-assisted treatment 
for opioid use disorder and nonmedical opioid abuse. Several cases have been 
documented as a result of maternal prescription opioid use, which is a result of an 
increase in physician prescribed opiates for pain management in the last decade. 1 
Methadone is the most common prescribed substance that results in NAS, and heroin is 
the most common illicit substance2. Buprenorphine is a newer legal substance that causes 
NAS, however limited studies have studied its safety and effects on infants with NAS16. 
Other substances that are less common but seen to cause NAS, include cocaine, selective 
serotonin reuptake inhibitors, and amphetamines2. Studies have shown that the timing of 
NAS withdrawal varies between different substances that mothers use. The variation is a 
result of different drugs have different half-lives of elimination. Heroin has a shorter half 
life than methadone resulting in an earlier onset of symptoms, usually within 24 hours, 
whereas withdrawal symptoms from methadone can take up to five days to manifest17.  
 
Pathophysiology of NAS 
 
Most prenatally exposed infants manifest some degree of withdrawal symptoms at birth, 
however, NAS expression and severity is extremely variable. The exact pathophysiology 
of opiate use during pregnancy on NAS development in an infant remains unknown and 
needs to be further studied. Current research explains that drugs are transferred from the 
mother to the fetus through the placenta while in utero. At birth, the trans-placental 
	  8 
transfer of these drugs is discontinued, causing the development of withdrawal in the 
infant18.  
Studies have shown that there is no relationship between the amount of 
methadone used during pregnancy and the severity of NAS symptoms displayed by an 
infant19. Since there is no a dose–response relationship between methadone exposure and 
NAS severity, physicians are unable to predict the neonatal consequences of prenatal 
opioid exposure for individual infants. However, it has been postulated that the infant’s 
inability to self-regulate behavioral and physiologic processes is due in large to the 
dysregulation of their ANS. The ANS is a crucial regulator of homeostasis and allows for 
extra-uterine adaptability in infants8.  
 
Autonomic Nervous System  
 
The ANS is divided into the parasympathetic and sympathetic branches, which adjust 
levels of activation to adapt to different situations. The parasympathetic branch is 
responsible for the regulation of organ functions, whereas the sympathetic branch is 
responsible for the fight-or-flight physiological changes such as increased HR in stressful 
situations20. Optimally, the sympathetic and parasympathetic branches should function 
together, such that an increase in sympathetic activation from baseline should result in a 
subsequent decrease in parasympathetic activation. When these two branches do not 
function in concert with one another, an individual has a dysfunction in their ANS.   
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A mother regulates physiological processes for a fetus while in utero. The burden 
of self-regulation is immediately put on the infant after birth. The ANS is the body’s 
control system that regulates bodily functions such as HR, respiration rate, digestion, and 
arousal20. The maturation of the ANS begins to develop while in utero, and continues to 
develop after birth into early childhood.   
Infants who are able to properly regulate their ANS are able to activate their 
sympathetic branch with some degree of deactivation of their parasympathetic branch, 
and demonstrate appropriate responses to internal and external stimuli by adapting their 
physiological behaviors. These infants are able to produce adaptive behaviors, such as 
crying to stimulate caregiving responses21.  
When an infant’s ANS is not properly developed at birth, as most notably studied 
in preterm infants, the infant is not able to self-regulate important bodily functions or 
adapt to stressors efficiently. The clinical presentation of infants with NAS, specifically 
the symptoms of sweating, fever, sneezing, and mottling22, provides evidence that these 
infants have impaired regulation of their ANS. Additionally, the disorganized rather than 
adaptive behaviors displayed by infants with NAS, often impair basic functions such as 
feeding, sleeping, and the ability to be alert and communicate clear behavioral cues to 
caregivers13. 
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Autonomic indices of regulation 
 
HR is a useful measure of ANS regulation in infants. HR is a net influence of the 
deactivation of the parasympathetic branch and activation of sympathetic branch.  The 
fluctuation in these two branches of the ANS accounts for variability in HR from beat to 
beat. An increase in HR to stimuli represents autonomic arousal and responsiveness. A 
moderate increase in HR in response to stimuli indicates a normal autonomic response. 
More extreme changes in HR indicate high levels of reactivity and dysfunction in the 
balance of the sympathetic and parasympathetic branches, reflecting a non-optimal 
response23.  
Natural changes in HR occur with respiration. During inspiration, the vagal 
impulse to the heart decreases, meaning there is a deceleration in parasympathetic branch 
activity, causing a subsequent increase in HR. During expiration, the vagal impulse to the 
heart increases, meaning there is there is no deceleration in parasympathetic activity, 
which causes a decrease in HR24. The variability in HR during the respiratory cycle has 
been coined HRV, and is a common parameter used to assess ANS function25. HRV is 
quantified by respiratory sinus arrhythmia (RSA). The time interval between heartbeats is 
referred to as the R-R interval. RSA is a measure of the difference of R-R intervals 
during inspiration and expiration. This computed difference reflects parasympathetic 
function and is a widely used index of cardiac vagal tone23.  
 A converse relationship exists between HR and RSA. As HR increases, RSA is 
suppressed. This is conceptually fitting, because RSA is a measure of parasympathetic 
	  11 
activity. When HR increases, parasympathetic activity decreases when in response to an 
increase in sympathetic activity. In optimal ANS function, RSA should be suppressed 
from baseline in response to stimuli. A lack of suppression of RSA to stimuli reflects an 
inability to suppress parasympathetic activity in response to increased sympathetic 
activity, illustrating ANS dysfunction.  
 Optimal baseline RSA measurements should be taken in the absence of external 
stimuli and when HR and respiratory rate are stable. In infants, this measurement is often 
taken in the setting of quiet sleep. Hathorn describes infants in quiet sleep as having 
stable patterns of breathing, whereas infants in active sleep have a more irregular pattern 
of breathing24.  
 
Polyvagal theory  
 
While traditionally the ANS in infants has been extensively studied in the context of 
sudden infant death syndrome and critical cardiac or respiratory conditions, 
neurophysiological research is shedding light on the findings that neuronal regulation not 
only plays an important role in physiological behaviors, but is critical to psychological 
functioning as well. Stephen Porges developed the Polyvagal theory, which states that the 
ANS plays an important role in regulating social, emotional, and behavioral systems8. 
The ability to regulate physiological and behavioral processes in infancy is a predictor 
later behavioral and psychosocial outcomes7. 
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Infants with higher levels of vagal tone at baseline, assessed by greater HRV, or 
who have higher levels of ANS functioning in response to a stressor, assessed by 
increased HR and decreased HRV, have been found to demonstrate higher levels of 
emotional regulation26. Therefore, assessment of an infant’s ability to regulate emotion 
can be made through assessment of vagal tone. An infant’s ability to regulate emotions 
plays a role in how an infant interacts with its caregiver, which consequently contributes 
to formation of attachment style27. An infant with greater emotional regulation is likely to 
have more prolonged and sustained interactions with its caregiver that leads to a securer 
attachment than an infant that is unable to regulate its emotions26.   
The relationship of ANS function and attachment is also conceptually fitting 
when comparing underlying mechanisms. Infants with secure attachment become 
distressed when their caregiver leaves, are not comfortable with a stranger, and return 
back to baseline when their mother returns28. This parallels the processes of adaptability 
that occur in infants that are able to properly regulate their ANS. These infants become 
distressed in the setting of a stressor, they attempt to adapt to the stressor by adjusting 
parasympathetic and sympathetic branch activation, and return to their baseline after the 
stressor is removed. Infants with insecure attachments do not react to the unfamiliar 
situations in the expected way that infants with secure attachments do29, similarly to how 
infants with ANS dysfunction do not react to stimuli the way infants with normal ANS 
function do3.  
The implications of the Polyvagal theory have motivated research to assess ANS 
in infancy more critically and establish long-term effects. High-risk infants, such as 
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preterm infants, exhibit dysregulation of their ANS30. Premature infants have higher HRs 
and less HRV at baseline than full-term infants, demonstrating an immature ANS31. The 
results of a study comparing preterm and full-term infants at baseline illustrated these 
finding quantitatively.  The preterm infants in the sample had a mean HR of 139 beats per 
minute (bpm) compared to the full-term infants who had a mean HR of 112 bpm. 
Similarly the mean HRV, which was measured by RSA, in preterm infants was 0.95 
millisecond2 (ms2) compared to a mean RSA of 1.12 ms2 in full term infants32.  This 
disparity between full-term and preterm infants exists because significant maturation of 
the ANS occurs between 31 and 38 weeks gestation33. Although the underlying 
mechanism of ANS dysfunction in infants with NAS remains unknown, these infants 
demonstrate similar ANS regulation difficulties as observed in preterm infants3.  
As proposed by Porges, vagal regulation and HR have been demonstrated as 
predictors of psychosocial outcomes in studies of preterm infants. Doussard-Roosevelt 
and colleagues showed that higher HR and lower RSA in fancy were associated with less 
behavioral regulation and poorer social skills at three years of age than lower HR and 
higher RSA30. Long-term developmental effects of NAS remain unstudied, however it 
can be postulated that infants with NAS are vulnerable to the same risk of developing 
negative behavioral outcomes as preterm infants since they exhibit the same ANS 
regulation difficulties. 
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Barriers of NAS 
 
Despite the evident clinical symptoms of withdrawal faced by infants with NAS, there are 
many other early life barriers that can be burdensome for this high-risk population.  
Separation of mother and infant has a profound impact on bonding in early days and 
weeks after birth, and can be detrimental for both physiologic and behavioral 
development29. In the setting of NAS, separation of mother and infant can be due to legal 
ramifications, drug-seeking behaviors of mother, or the hospitalization34.  
In 2014, the American Congress of Obstetricians and Gynecologists retracted 
criminal laws that threatened severe legal consequences, such as incarceration, of women 
who abused drugs prenatally since this action deterred women from seeking proper 
prenatal care35. However, legislative policies regarding testing and reporting of maternal 
opiate use remain controversial and vary between states. Eighteen states consider in utero 
exposure to opiates child abuse, and three states consider it grounds for maternal 
commitment. Fifteen states require mandatory reporting of use of substances in 
pregnancy, and four states have mandatory testing of all pregnant women36.   
In Massachusetts, health care providers are required to notify the Department of 
Child and Family Services (DCF) when there is a suspicion of in-utero substance 
exposure as these infants are identified as having experienced “physical injury”37. A 51A 
report of child abuse and neglect is filed and opens a DCF investigation about the 
suitability of the mother as the primary care provider of the child. As of January 2013, 
Massachusetts was among the first states to revise the policy to allow screening of 51A 
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reports of substance exposed newborns in maternal use of methadone, buprenorphine, 
buprenorphine with naloxone, or another appropriately prescribed medication without 
further investigation38. Of the remaining cases of substance-exposed infants that warrant 
further DCF investigation, about fifty percent are placed in state custody39, resulting in 
separation of mother and infant and absence of a caregiver.  
Infants with NAS require pharmacological treatment with morphine or 
methadone, which is administered in a NICU setting because of the additional medical 
support and monitoring required due to risk of respiratory depression40. NICUs are not 
able to accommodate the extra beds or staffing to care for mothers post-delivery, so 
mothers and infants are often separated for extended periods of time and nurses step in to 
provide necessary care41.  
John Bowlby, the founder of attachment theory, described the infant as needing 
proximity and closeness to form strong bonds and attachment with its mother29. This 
natural process of attachment in the early days of life is often interrupted in infants with 
NAS, due to separation of mother and infant, along with multiple health care providers 
assessing for symptoms of withdrawal and providing care for the infant. The quality of 
mother-infant attachment is determined by their interactions and the response and care 
provided. Infants are predisposed with regulatory mechanisms, such as crying, that 
stimulate care and bolster their attachment with their mother. However, infants with NAS 
are unable to regulate these mechanisms due to the dysregulation of their ANS. The 
inability to communicate clearly detrimentally impacts the formation of mother-infant 
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relationship, as the mother is often unable to interpret the infant’s cues correctly and 
often overcompensates21. 
 In the discussion of NAS, the focus is often put on the infant and the evaluation of 
the mother’s well being is often neglected. Mother’s health is important and is reflected 
in the care provided to the infant. Even for women receiving methadone treatment, 
addiction remains a chronic, lifelong disorder that may come with consequences during a 
pregnancy. Dosages are often changed and higher doses may be required for pain 
resulting in an unconventional fatigue, which could impact the mother’s ability to 
respond and nurture her infant.  Additionally, the psychological health of mothers often 
suffers because of the burden of guilt and helplessness of watching their infant suffer. 
There is often added psychological stress due to the psychosocial stigmas of these 
mothers. Cleveland and Gill conducted a study on the hospital experiences of mothers of 
infants with NAS. The study revealed that mothers felt that they were negatively judged 
and stereotyped by health care providers and other family members for the past drug 
addiction42. Subsequent studies have shown that maternal involvement in caring for their 
infant during treatment reduces feelings of guilt, helplessness, and depression. 
Additionally, these mothers continue to provide more sensitive care for their infants after 
hospitalization and are more likely to remain abstinent from substances43. These positive 
outcomes suggest that future treatment interventions should emphasize maternal 
involvement. 
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Skin-to-skin interventions  
 
Skin-to-skin contact is an innate maternal method of providing comfort to a newborn. 
Skin-to-skin contact results in the release of oxytocin, which is a hormone that is released 
in both the mother and infant that reduces stress and promotes bonding and attachment 
between mother and infant44. 
KC is a skin-to-skin intervention that was first applied in Borgota, Columbia 
during a period of incubator shortages for preterm infants in the 1970s45. The method is 
implemented by placing an undressed infant directly between a mothers breast, 
integrating rhythmic, thermal, and sensory components of stimulation46. KC is a 
inexpensive, readily available, non-invasive therapy that has become a standard of care 
option for infants in the US, although the therapy remains underutilized46. 
KC was originally extensively studied as a method of reducing morbidity in 
developing countries where incubators were not readily available5, but has since been 
explored as adjunct treatment of infants in developed countries and found to have 
profound benefits. Studies show that administration of KC in infants increases their 
ability to maintain body temperature47, stabilizes cardiac functioning47, and improve sleep 
organization, resulting in increased quiet sleep and longer sleep cycles48 . KC has also 
been demonstrated to increase weight and head circumference49 in the first few weeks of 
life, and lower risk of serious infections, such as sepsis and pneumonia, in the first six 
months of life45. Other studies have illustrated the positive implications of KC on 
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breastfeeding, showing that KC is correlated with outcomes of longer durations and 
exclusivity of breastfeeding50, and even increased milk supply in mothers51.  
Recent studies in preterm infants demonstrate that KC serves as method of 
facilitating ANS maturation. The mechanism behind this modification in ANS remains 
unstudied, but is likely because KC stimulates peripheral nerves that activate the vagus 
nerve, which subsequently decreases HR and increases RSA. If the findings in preterm 
infants are demonstrated in infants with NAS, this could have significant implications for 
this high-risk population.   
 
Existing Research  
 
Dysregulation of ANS in NAS  
 
For years it was believed that the exact mechanisms of NAS were indiscernible due to the 
high rates of poly-drug abuse among these mothers. Lauren Jansson and her colleagues 
were the first to propose that the variability in NAS may be rooted in differences in 
maternal or infant functioning. They sought to explore potential predictors of NAS 
severity in infants based on individual maternal differences. The variables they focused 
on included the quantity and duration of maternal opiate use, poly-drug use, and 
individual maternal intrinsic factors, specifically vagal reactivity to methadone 
administration. The researchers chose to measure vagal tone as an intrinsic difference in 
maternal functioning based off prior evidence suggesting that infants with NAS display 
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homeostatic instability. They assessed fifty pregnant mothers enrolled in a methadone 
maintenance treatment facility. Data was gathered via interpreting patient histories and 
electrocardiograms. Electrocardiogram recordings were taken after methadone 
administration when mothers were at 36 weeks gestation. Their results showed that 
mothers who experienced suppression or activation of vagal tone during administration of 
methadone were more likely to give birth to infants who developed more severe 
symptomatology of NAS (F (2,44) = 4.15, p < 0.05) than mothers whose vagal tone 
remained stable during administration14. These infants subsequently required more 
pharmacological treatment (F (2,44) = 3.39, p < 0.05).  
Although no direct associations could be made by this study, its findings were 
pivotal in suggesting disruption in maternal autonomic functioning during administration 
of methadone in pregnancy, regardless of if the instability was suppression or attenuation, 
may play a role as a mechanism of subsequent NAS expression in infants. Since the 
formation of an individuals’ ANS begins in utero52, it could be hypothesized that an 
infant’s ability to regulate is reflective of their mother’s ability to regulate and warrants 
further exploration in determining the pathophysiology of NAS.  
  Jansson and colleagues later built on their previous research and conducted 
another study to evaluate the ANS function in infants with NAS, expecting homeostatic 
instability in infants with NAS to be due to lower vagal tone as seen in high-risk preterm 
infants53. They recruited sixty-six women from the Center for Addiction and Pregnancy 
in Baltimore, Maryland, which provided obstetric care, methadone maintenance, and 
other prenatal resources to pregnant women with drug dependency. Enrollment criteria 
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required abstinence from alcohol, however all participants smoked cigarettes. The 
parameters used to measure autonomic regulation included heart period, assessed as 
increased HR, and vagal tone. Sixty-four infants were ultimately included in the data 
analysis, forty-eight of which required pharmacological treatment. Heart period and vagal 
tone were used as measures of autonomic regulation. Their findings demonstrated that 
infants with lower vagal tone (F (1, 59) = 19.88, p < .0001) and heart period (F (1, 
59) = 5.95, p < .05) on day 1 had more severe NAS by day 3. Additionally, the findings 
suggested that although males and females are equally vulnerable to developing NAS (F 
(1, 62) = 6.03, p < .05), males have higher NAS expression (81% vs. 69%), require more 
pharmacological treatment (13.4 days vs. 9.0 days; t (46) = 2.25, p < .05), and have 
longer hospitalizations (15.9 vs. 12.0, t (46) = 2.09, p < 05) than females. This study 
confirmed that autonomic dysregulation played a role in severity of NAS expression. It 
also shed light on the finding that male ANS functioning may be more vulnerable to 
female ANS functioning. 
As discussed previously, proper ANS regulation suggests that one has the ability 
to adjust levels of parasympathetic and sympathetic involvement under different 
situations. Hambleton and colleagues decided to look into how the ANS regulation 
differed in infants with NAS compared with normal, full term infants in their abilities to 
regulate by observing them in different situations. They conducted a study looking at 
ANS function during non-nutritive and nutritive sucking in prenatal opiate-exposed 
infants compared to control term infants. They chose non-nutritive and nutritive sucking 
as their variables, as feeding and digestion should elicit an increase in autonomic 
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functioning54. Twenty-four infants were included in the study; ten infants were in the 
control group and fourteen were exposed to opiates prenatally.  HR and HRV were 
assessed as measures of autonomic stability. The results of the study showed that infants 
with NAS had greater HR during non-nutritive sucking with a mean of 157 beats per 
minute compared to the control group with a mean of 143 beats per minute (p < 0.01). 
Unlike the control group, who had an expected increase in HR during nutritive sucking, 
the infants with NAS had no change in HR in nutritive sucking from non-nutritive 
sucking (p < 0.002). Additionally, the exposed infants exhibited statistically significant 
increases in low frequency (mean difference = -0.18, p= 0.04) and high frequency (mean 
difference = -0.4075, p = 0.0027) spectral analyses of RSA during non-nutritive and 
nutritive suckling periods than the control group, showing lower HRV55. These findings 
are demonstrative of activation of both parasympathetic and sympathetic branches in 
response to a change in stimulus instead of the normal converse functioning of the two 
branches. These inappropriate responses to stimuli further illustrate ANS dysfunction in 
these infants. 
These studies shed some light on the pathophysiology of NAS. The findings of 
these three studies demonstrate that the dysregulation of the ANS is a fundamental 
underlying mechanism in the development of NAS in infants with prenatal-opiate 
exposure. Tailored treatments that focus directly on improving ANS regulation of these 
infants could have pivotal implications.  
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Current skin-to-skin interventions in infants experiencing NAS  
 
To date, treatments in NAS have not focused directly on modifying ANS function. 
Overall, non-pharmacological interventions require further exploration of their efficacy 
as treatments in NAS, but may serve as platforms to build upon as potential methods of 
improving ANS function in these infants. Direct skin-to-skin therapies can increase vagal 
stimulation and play a role in ANS activation. Although KC has been established as 
intervention that improves ANS in other infant populations, other skin-to-skin 
interventions may play a role as well. Current studies in infants with NAS focus on the 
short-term effects, such as NAS severity and length of hospitalization, but could be 
expanded to assess ANS in the future.    
Breast-feeding in NAS has extensively been studied as it serves as a method to 
transfer methadone, improves the bonding between mother and infant, and also allows the 
mother to feel like an effective caregiver24. The AAP removed breastfeeding restrictions 
for methadone-maintained mother in 20012, after findings revealed that methadone levels 
in breast milk were minimal even when mothers were on high methadone doses56. 
Researchers in Norway conducted a retrospective study to determine the effects of 
breastfeeding on incidence and duration of NAS. The study included 124 infants that 
were prenatally exposed to opiates from the years 1999 to 2009. Data were collected 
through questionnaires and medical information from hospitals. Their findings showed 
that 53% of infants who were breast-fed developed NAS, whereas 80% of infants who 
were not breast-fed developed the syndrome. Additionally, their data illustrated that 
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infants who were breastfed (mean = 28.6 +/- 19.1 days) required significantly less 
pharmacological treatment than infants that were formula fed (mean = 46.7 +/- 26.3 days, 
p < 0.05)57. Although no direct connections of breastfeeding on ANS maturation have 
been made, nutritive sucking has been illustrated to have an effect on ANS regulation in 
infants. RSA decreases during nutritive sucking, whereas HR increases as a result of the 
gustatory stimulus58. For this reason, ANS maturation due to breastfeeding may be an 
area for future exploration in infants with NAS. 
Rooming in is a treatment option that has recently been gaining attention in NAS 
research. The current standard of care treatment for an infant with NAS is treatment in 
the NICU. Rooming-in is an intervention that allows the newborn and mother to co-
habitat in the same room while receiving NAS treatment, allowing for increased mother-
infant contact and family involvement in treatment management. Holmes and colleagues 
conducted a quality improvement project at a 63-bed/16-bassinette rural children’s 
hospital that provides pediatric care for most of New Hampshire and some of Vermont. 
The intervention took place in phases from March 2012 to February 2015. A total of one 
hundred sixty three infants were included in the study; fifty-four infants were evaluated 
in the pre-intervention year, sixty-one infants in year 1, and forty-eight infants in year 2. 
The transition to full rooming-in took place over time, and required additional team 
training and working closely with families, but the results proved that the quality 
improvement project to be a successful treatment intervention. After implementing 
rooming-in, infants that required pharmacological treatment dropped from a baseline of 
47% to 27% and the cumulative average morphine dose administered dropped from 13.7 
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to 6.6 mg. Additionally, length of hospital stay reduced from an average of 16.9 days to 
12.3 days, and hospital costs dropped significantly (from baseline of $11,000 to $5300 
post-intervention, p < 0.01)59. This study is pivotal for transitioning standard of care for 
infants with NAS from NICU settings to rooming in settings. Rooming in creates an 
environment that allows greater levels of direct contact of mother and infants. Although 
this study didn’t quantify the amount of direct skin-to-skin contact these mother-infant 
dyads had, future studies of rooming in could compare the difference in amount of direct 
skin-to-skin contact infants in the NICU setting have compared to rooming in.  
KC has several benefits in healthy and preterm infants. The current literature of 
KC in the NAS population is minimal, and is limited to two case reports. Ludington-Hoe 
& Abouelfettoh compared two substance- abusing mothers as they provided varying 
amount of KC over the first five days of life. The first mother provided 60-70 minutes of 
KC for the first 2 days, whereas the second mother provided 30 minutes - 11 hours per 
day for the first 5 days. The findings showed that NAS severity did not improve with a 60 
- 80 minutes of KC, however, three or more hours decreased NAS severity substantially 
to scores below 8, which is the clinically cut-off for requiring pharmacological treatment. 
However, the scores rose again within an hour after termination of intervention48. 
Although this study shows promise for the exploration of KC in infants with NAS, it has 
several limitations in confounders. The most critical limitation is the sample size of two 
infants, of which the first infant required resuscitation immediately after delivery and 
exhibited signs of respiratory distress through first few days of life. Other confounders 
include differences in how NAS severity was scored and varying durations and frequency 
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of KC intervention. Because of these limitations and confounding variables, these case 
reports serve as initial framework for further evaluation of KC as an effective treatment. 
Since KC has been demonstrated to have many effects, including maturation of ANS 
function, in other high-risk infant populations, the intervention warrants further study in 
the NAS population. 
 
Effects of KC on ANS in preterm infants  
 
Existing studies focusing on modifying ANS function in infants are currently limited to 
preterm infant literature. Similar to infants with NAS, preterm infants are born with 
difficulty regulating their ANS. The underlying mechanism behind this dysregulation in 
preterm infants is most attributable to immaturity of ANS due to lack of development 
because of their early gestational age. Although this mechanism is not the same as that of 
infants with NAS, preterm infants and infants with NAS exhibit similar ANS functioning 
in infancy, including increased fluctuations in HR and less HR variability. Some studies 
have shown to successfully modify and help mature the ANS of preterm infants and may 
serve as the groundwork for exploration of interventions that modify ANS function in 
infants with NAS.  
Feldman and Eidelman were one of the first to conduct a study that observed the 
effects of KC on autonomic and neurobehavioral maturation in preterm infants. The study 
assessed seventy preterm infants; thirty-five infants were put in the experimental group 
and received KC for an average of 29.8 hours over an average of 24.3 days and the other 
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thirty-five infants were put in the control group that did not receive KC. Vagal tone was 
the parameter that was used to assess autonomic maturation, and was first calculated 10 
minutes administration of KC for the first time and then again at 37 weeks gestational 
age. The results illustrated that the KC intervention allowed for more rapid maturation of 
vagal tone compared to the infants that did not receive the intervention (F (2,52), 
p<0.0001). Additionally, the infants given the intervention displayed greater physiologic 
regulation demonstrated by longer periods of quiet sleep and alert wakefulness (F (6, 
61)=3.37, p=0.008)60. This study set the groundwork for more exploration of KC as a 
modifier of ANS in preterm infants. 
An additional benefit of KC is that it has been shown to reduce the amount of 
procedural pain experienced by preterm infants. Infants with NAS are subjected to 
several heel sticks for lab draws and administration of morphine. These procedures 
invoke pain and stress in the infant, which in consequence activates the ANS. Cong 
studied how implementing KC affected autonomic pain responses in preterm infants 
during a heel stick procedure. The study followed a crossover design, meaning each 
participant was exposed to each intervention. Ultimately, twenty six participants were 
observed under three conditions: incubator care prior to heel stick, thirty minutes of KC 
prior to heel stick, and fifteen minutes of KC prior to heel stick. HR changes were the 
parameter measured to assess change in autonomic regulation. The baseline means HRs 
were not different between treatment groups. The results showed that infants had less 
fluctuation in HR after they received 15 minutes (14.36 +/- 15.41, p < .05; 13.27 +/- 8.67, 
p < .05) or 30 minutes (13.77 +/- 9.3, p < .05; 14.05 +/- 8.67, p < .05) of KC than 
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standard incubator care (11.40 +/- 15.42, p < .05; 20.08 +/- 10.98, p < .05) after 30 and 
120 seconds. Additionally, infants had significantly greater HRV after 30 minutes of KC 
than standard incubator care (p < .05). This study illustrates that even short duration of 
KC allow for decreased fluctuation of ANS in response to a stressor6. 
Since ANS infancy has been found to be a predictor of future behavioral 
outcomes, it is important to study if early life modifications of ANS have similar results 
on outcomes as infants born with mature ANS function. Limited research has looked at 
the role of early interventions enhances ANS over time. Feldman and colleagues 
conducted a longitudinal study to examine the long-term implication of the KC 
intervention in the first few weeks of life in preterm infants. The study included one 
hundred forty six mother infant dyads over the course of 10 years. The experimental 
group consisted of seventy-three infants who received one-hour of KC treatment for 14 
consecutive days while in the NICU and the control group consisted of seventy-three 
infants who received standard incubator care. Infants and parents were assessed seven 
times over the course of 10 years. These assessments occurred at hospital discharge and 
then again when the child was 3, 6, 12, and 24 months, and at 5 and 10 years. By the 10-
year point, only one hundred seventeen children remained in the study due to attrition. . 
The results of the study illustrated that infants who received KC had higher baseline RSA 
in infancy (F (2,112) = 4.992, p = .008) and at 10 years (F (3,83) = 3.30, p=. 025) than 
infants that did not receive the intervention. Their study finding that RSA in infancy 
correlated with RSA at 10 year RSA (r=. 33, p=. 001) and “attenuated stress response, 
more mature autonomic functioning, organized sleep, better cognitive control, and more 
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reciprocal mother–child relationship” 61 were consistent with previous knowledge that 
ANS in infancy is a predictor of future behaviors. These findings are pivotal in 
demonstrating that the effects of early skin-to-skin interventions in preterm infants 
permanently modify their ANS, and have life-long implications on their development and 
attachment relationships. Preterm infants exhibit difficulty regulating behavioral and 
physiological functions at birth in the same was as infants with NAS, therefore these 
findings allow encouragement that the same effects will hold for infants born with NAS.  
These studies, summarized in the Table 1, illustrate the benefits of KC on ANS 
maturation in preterm infants. It is likely that when this intervention is applied to the 
NAS population, there will be similar physiological results in their ANS functioning. 
This proposed study seeks to explore if these findings of KC on ANS are generalizable in 
infants with NAS.    
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Table 1. Existing studies illustrating the effects of KC on ANS function in preterm 
infants 
 
Researcher(s), 
Year 
 
Sample Size 
 
Intervention 
 
ANS 
Variable 
Findings 
Cong, 2012 
 
N = 26   
*Cross-over 
design 
- KC30: N = 22 
- KC15: N = 25 
- IC: N = 23 
  
KC prior to 
painful heel 
stick 
procedure  
– 3 sequences 
of 
interventions 
(KC30, 
KC15, IC)  
HR and 
HRV  
- Greater change in HR in 
IC than KC30 and KC15 
during heel stick at 30 
seconds 
- IC  (22.40 +/- 
15.42, p < .05)  
- KC30 (13.77 +/- 
9.3, p < .05)  
- KC15 (14.36 +/- 
15.41, p < .05)  
 
- Greater change in HR in 
IC than KC30 and KC15 
during heel stick at 120 
seconds 
- IC  (20.08 +/- 
10.98, p < .05))  
- KC30 (14.05 +/- 
8.67, p < .05)  
- KC15 (13.27 +/- 
8.67, p < .05)  
 
- HRV was significantly 
different in IC, KC30, and 
KC15 at low frequency (F 
(2,44) = 3.55, p < .05) with 
more low frequency in IC 
than K30 (p < .05) -> 
demonstrating greater HRV 
in K30 
 
- HRV was significantly 
different in IC, KC30, and 
KC15 at high frequency (F 
(2,42) = 3.51, p < .05) with 
more high frequency in IC 
than K30 (p < .05) 
demonstrating greater HRV 
in K30 
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Researcher(s), 
Year 
 
Sample Size 
 
Intervention 
 
ANS 
Variable 
Findings 
Feldman & 
Eidelman, 2003 
 
N = 70  
- E: N = 35 
- C: N= 35  
 
KC  
- At least 1 
hour KC daily 
for 14 days 
 
RSA 
 
-More rapid maturation of 
vagal tone between 32 and 
37 weeks' GA (F (2,52), 
p<0.0001)  
Feldman, 
Rosenthal, & 
Eidelman, 2014 
 
146  
- E: N = 73 
- C: N = 73 
*Longitudinal 
study  
KC  
- At least 1 
hour KC daily 
for 14 days 
 
RSA   - KC had higher baseline 
RSA in infancy (F (2,112) 
= 4.992, p = .008) than no 
KC 
- KC had higher baseline 
RSA after 10 years (F 
(3,83) = 3.30, p=. 025) than 
no KC 
- Neonatal RSA correlated 
with 10 year RSA (r=. 33, 
p=. 001)  
- Long term improvement 
of ANS functioning, 
organized sleep, cognitive 
control, and reciprocal 
mother-child relationship 
Notes: KC30 = 30 minutes of KC; KC15 = 15 minutes of KC; IC = Incubator care; HR = Heart rate; E = 
Experimental group; C = Control group   
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METHODS 
Study design 
This study aims to serve as a pilot study to provide preliminary data on baseline ANS 
function in infants with NAS. Additionally, it intends to examine the role of KC on ANS 
maturation in these infants. Since KC is a standard clinical option of infant care, 
randomization of participation in this study is precluded. Instead a prospective cohort 
study will be conducted to observe the physiological implications of KC on the 
neuromaturation trajectory of ANS function in infants with NAS during their 
hospitalization. The exposure of interest in this study is one-hour of daily KC for 14 
consecutive days. The main outcome measure is improvement in ANS function measured 
by HR and HRV.  
  
Study population and sampling 
An epidemiological statistics calculator was used to determine the sample size of this 
study using an alpha value of 0.05, beta value of 0.8, percent of unexposed with outcome 
of 20, and relative risk of 2.0. A sample size of 83 infants would be required for each 
cohort to yield a significant power62.  The relative risk was determined with an expected 
main outcome measure increase of 100%. Data in preterm infants demonstrated an 
increase from baseline mean RSA of 1.30 to 2.32 after KC, when RSA was reassessed 
three weeks after completion of KC. A slightly greater outcome measure is expected in 
the proposed study since the RSA outcome will be reassessed directly after completion of 
the KC intervention.  
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Intervention  
KC will be administered for one-hour durations daily for consecutive days to the 
experimental cohort. Dividers will be put up to ensure privacy of mother during KC 
administration. Infants will be undressed, except for caps and diapers, and placed 
between their mothers’ breasts. Mothers may choose to provide KC while recumbent in 
bed or while laying back in a rocking chair. Infants will remain on cardiorespiratory 
monitoring. Nurses will record exact times of administration and termination of mother-
infant direct skin-to-skin KC. Periods of separation for restroom breaks or diaper changes 
will not be included in the intervention duration, but will be recorded.  
The control cohort will receive standard care treatment from nurses and health 
care staff without supplementation of KC. All other treatment measures will remain 
standardized between the three cohorts.  
  
Study variables and measures 
Baseline demographic and medical information will be collected from mothers upon 
enrollment, and supplemented by existing data in BMC’s electronic medical record 
(EMR). (Listed in Table 2) Biomedical data of infant will be gathered and recorded at 
birth. (Listed in Table 3)  
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Table 2. Maternal demographic information to be collected.  
Maternal age/race/ethnicity 
Socio-economic Status 
History of substance use/duration/quantity  
Gravid/Parity 
HIV/Hepatitis C status 
Education level 
Occupation 
Pregnancy complications  
 
Table 3. Infant biomedical information to be collected. 
Sex 
Gestational age 
Mode of delivery  
Birth weight 
Apgar scores 
Finnegan NAS scores/times 
NAS medication administered/dosage/ frequency 
Post-natal feeding method  
 
NAS Withdrawal 
All infants will be evaluated for clinical symptoms of withdrawal at birth and every four 
hours subsequently after, as set by the AAP as standard guidelines for evaluation of NAS. 
The Modified Finnegan’s Neonatal Abstinence Scoring Tool63 will be applied (see 
Appendix) for symptom assessment along with initiation and management of 
pharmacological therapy.   
 
ANS Functioning    
HR and HRV will be used to assess autonomic functioning in all infants.  
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Continuous cardiorespiratory monitoring is a standard of care measure for infants 
prenatally exposed to opiates because of increased risk of seizures as a symptom of NAS 
and increased risk of respiratory depression secondary to morphine administration and 
risk40, and will be collected for all infants in this study. Interval data from the 
cardiorespiratory recordings will be used to assess HR and calculate RSA, the 
measurement that will be used to assess HRV. 
  
Recruitment 
Two cohorts will be recruited to participant in this study; one cohort will consist of the 
experimental arm that will receiving one-hour of KC daily and the other cohort will 
consist of the control arm that will not receive the KC intervention.  
Pregnant mothers who are actively using opiates prenatally and plan to assume the 
role of primary caregiver for their infant upon birth will be recruited to participate in the 
experimental cohort, Cohort 1, unless they meet any of the exclusion criteria, outlined in 
Table 3. A specialized nurse trained in implementing KC will counsel these mothers 
about the intervention. To enroll, the mothers must agree and consent to provide one- 
hour of continuous KC for at least 14 days while their infant is in the hospital receiving 
treatment for NAS. Mothers who do not want to provide any KC for their infant may 
choose to participate in the control cohort instead of the experimental cohort.  
The control cohort, Cohort 2, will be recruited from infants that will be put 
directly in the custody of the State, as they will not have a mother to provide the 
intervention. This study will not be interfering with the standard of care given to these 
	  35 
infants and no additional burden will be put on the infants, as all data that will be used in 
analysis is considered critical and mandatory in the care of infants with NAS. DCF will 
be consulted for consent to include these infants in this study.  
The study sample will be recruited from Boston Medical Center (BMC). BMC 
reports treating approximately 100-150 drug-exposed infants with NAS each year64. The 
Massachusetts DCF responded to about 2,000 cases of drug-exposed infants. Of these 
cases, a quarter of the infants were removed from their mothers and placed into custody 
of the State65.  Assuming the same proportion of infants is removed at BMC, 
approximately 37 of the 150 infants of the BMC study will be taken into custody by the 
State. The study is anticipated to span over a recruitment period of three years to ensure 
that sufficient sample sizes are studied.  
 
Table 4. Participant exclusion criteria for mother and infant.  
 
Mother Infant  
- Multiple pregnancy  - Gestational age <37 weeks 
- Significant pregnancy or pre-existing 
medical conditions 
- Birth weight <2500 g  
- Alcohol dependence - Major organ dysfunction or neurological, 
congenital, or genetics abnormalities 
- Use of other illicit substances other than 
opiates  
- Physical findings that would comprise the 
safety of the subject  
 
 
Data collection 
Maternal data for Cohort 1 will be collected directly from mother at the time of 
enrollment in study. Maternal demographic and medical information for Cohort 2 will be 
gathered using BMC’s EMR. Each infant will be assigned a study number; all data will 
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be de-identified and linked only to study numbers. A password-protected file will be kept 
to link participants with their study numbers during data collection and analysis, and will 
be deleted at completion of the study.  
Biomedical data of infant, listed in Table 2, will be gathered upon delivery.  
Comprehensive assessments of NAS symptoms and severity using the Modified Finnegan 
Scoring System will begin at birth and be measured every 4 hours by nurses. When an 
infant has two consecutive scores of 12 or higher or three consecutive scores of 8 or 
higher, pharmacological treatment will be started. Nurses will keep detailed logs of 
dosage amounts, frequency, and titration requirements.  
Infants in both cohorts will be kept on continuous cardiorespiratory monitoring 
during hospitalization. The first administration of KC in Cohort 1 will be implemented 
immediately after birth, or as soon as clinical stability of both mother and infant allows. 
Nurses will keep detailed logs of when each administration takes place, making notes of 
any interruptions.  
 
Data analysis 
Upon completion of data collection, participant’s data will be entered into a statistical 
computing program. A statistician group will be consulted to perform all data analysis. 
Univariate analysis of individual differences in demographic data, birth characteristics, 
and NAS severity will be assessed for all study subjects.  
HR and HRV will be determined by assessing periods of 10-minute segments of 
cardiorespiratory monitoring during quiet sleep from each of the following time points: 
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after birth, after 48 hours, on day 7, and on day 14. Measurements of RSA will be 
calculated to accurately assess HRV. RSA measures will be electronically computed 
using standardized HRV analysis software, Porges’ MXEdit system61.  
Mean HR and RSA will be determined for each cohort for each time point to 
determine the trajectories of ANS. The cohort sample’s trajectory will be used as an 
evaluation of baseline maturation for infants over the first 14 days of life. Evolutionary 
comparisons of differences between the two cohorts will be assessed using a series of 
paired t-tests. If a statistically significance emerges between the two cohorts for Day 14 
data, chi-squared tests of independence and analysis of variance will be conducted.  
Using a dichotomous outcome of improvement of ANS compared to no 
improvement as the main outcome measure and one-hour daily for 14 days as the 
exposure, a relative risk will be assessed for this sample. (See 2 for contingency table.)  
 
Figure 2. Contingency table for relative risk.  
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Timeline and resources 
Table 5. Projected timeline 
September 2017 – December 2017 - IRB Proposal submitted for 
approval 
- DCF consulted for consent 
January 2018 – December 2020 - Recruitment of participants 
- Data collection  
January 2021 – February 2021 - Completion of data collection 
- Data consolidation and analysis 
March 2021 – April 2021  - Preparation and submission of 
publication 
 
Table 6. Resources 
Administrative/ Clinical Support  
• Study coordinator / Primary investigator 
• KC Nurse Specialist  
• NICU medical and nursing specialists trained in managing the needs of 
NAS 
• Statistician group  
Logistical Supplies  
• IRB approval 
• DCF consent  
• Private rooms for administration of KC 
• Infant cardiorespiratory monitors 
• HRV computer software  
 
Institutional Review Board 
The study protocol will be submitted to the Institutional Review Board for approval. 
Infants with NAS are a high-risk population given their clinical symptomatology and 
requirement of morphine treatment, therefore this study will warrant full board review to 
protect the human participants.   
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CONCLUSION 
Discussion 
Optimal non-pharmacological treatment of NAS has not been established, with current 
studies limited to short term effects, such as NAS score severity and length of 
hospitalization. KC has been a topic of interest in infant research for several years, but it 
was not until recently that it was targeted specifically on modifying ANS function in 
preterm infants because of the prospect of its ability to stimulate vagal activation. This 
reasoning proved to be true in the preterm infant studied. Findings demonstrate that there 
is significant improvement of ANS development when KC is implemented. If replicable 
in infants with NAS, this approach to care could be pivotal in formulating the future of 
non-pharmacological treatment practices for these infants.  
Existing research has demonstrated that infants with NAS have difficulty in 
regulating their ANS, and that the degree of dysfunction is correlated with NAS severity3. 
However, researchers have not yet delved into establishing the trajectory of maturation of 
ANS after birth in these infants or methods of improving ANS function. This study was 
designed to attend to these current gaps in literature. 
KC is coined as a standard of care option and is considered a first line care 
strategy of infants. However, it has not been utilized as common technique implemented 
in infants with NAS due to standard of treatment being in a NICU setting. Since this 
study will be the first to examine KC in a study with both experimental and control arms, 
an important ethical consideration regarding the feasibility of the design had to be taken 
into account. Typically empirical testing of an exposure that would deny standard of care 
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measures to subjects is unethical. The level of DCF involvement and high proportion of 
infants that are taken into custody by the State allow for some ambiguity in this 
population. KC is only readily available if an infant’s mother is available. Infants taken 
into custody of the State do not have a caregiver to provide KC; therefore including them 
in the control cohort does not deny them of care they would normally receive. If the 
findings of this study prove to be consistent to the findings in preterm infants, it would be 
good measure to conduct subsequent studies to examine the plausibility of alternate 
providers of KC for these infants, such as trained volunteers.  
 This study is among the first to explore this intervention on infants with NAS. For 
this reason, it concurrently intends to evaluate the feasibility, infant and maternal 
tolerance, recruitment challenges, and methodological issues of KC in this population for 
future research. Because of the novelty, the limitations in this study expose directions for 
prospective studies.  
A major limitation of this study is the lack of existing statistics and data in the 
NAS population. The study was designed with a heavy influence of existing literature of 
preterm infants and relies on assumptions that these findings are generalizable to infants 
with NAS. In particular, the frequency and duration of KC intervention in this study was 
implemented based on the precedent set in preterm infants of one-hour daily for 14 days. 
The single case report of KC in infants with NAS suggests that a minimal of 3 hours of 
KC daily is necessary for observable benefits in clinical symptomology48. Since there is 
variability in the mechanisms behind ANS dysfunction in infants with NAS and preterm 
infants, it is possible that there could be different requirements for the application of this 
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intervention between the two groups. Future studies should explore the impact of longer 
durations of KC on infants with NAS and establish a standardized duration and frequency 
at which optimal benefits are seen.  
Although the prevalence of NAS is increasing rapidly, most institutions only care 
for a relatively small sample of these infants each year. This study sample will be limited 
to infants born at BMC. This is beneficial as it allows for a degree of standardization of 
demographics and care among the participants enrolled, but also poses a critical 
limitation. BMC cares for the largest population of infants with NAS in Massachusetts, 
estimates treating 100-150 infants born with NAS each year. BMC is also the largest 
safety net hospital in New England and treats the largest volume of patients with opiate 
issues in the Boston area, reporting 37% of all Boston EMS transports for opiate issues 
being brought to BMC in 2015.66 The hospital is located in what is referred to as 
Boston’s “Methadone Mile”, an area that is congested with an open-air illicit drug market 
that is being battled by methadone clinics and providers at BMC65. The vulnerability of 
the opiate-abusing population brought to BMC has led them to increase the number of 
services available to these patients, including a prenatal substance use disorder clinic that 
transitions mothers to maintenance treatment during their pregnancy66. Over 90% of 
infants born with NAS at BMC are born to mothers on methadone or buprenorphine 
maintenance22. Because of the increased focus at BMC on providing care for patients 
with illicit opiate abuse problems, the samples recruited in this study may be less 
generalizable to all populations of infants born with NAS. Future studies should include 
samples for more institutions.  
	  42 
This study was designed with the influence of existing literature of preterm 
infants. This study serve as a pilot study in infants with NAS and provide preliminary 
data to establish the role of KC as a modifier of ANS function, therefore its findings and 
limitations will function as the framework for future directions of research in the field.  
Summary 
Recent literature illustrates that dysregulation of ANS plays a role in clinical 
symptomatology and severity of NAS. Studies in preterm infants, a population of infants 
that exhibit similar ANS regulation difficulties at birth, depict that implementing the KC 
intervention in the first few weeks of life allows for modification of ANS function. ANS 
function in infancy is a predictor of future psychosocial behavioral functioning, so 
modifications in the first few weeks of life could prove to have pivotal implications for 
infants with NAS. 
KC is not currently standard of care for infants with NAS, but is a cost-effective, 
readily available, low risk non-pharmacological method that warrants further study as a 
therapeutic intervention for infants with NAS. This proposed study will investigate the 
KC intervention in infants with NAS, in hopes that it will simulate the same findings seen 
in preterm infants. 
Clinical and/or public health significance 
This study tests a very novel approach for improving an important neurobehavioral 
complication of NAS. If KC proves to be effective in modifying ANS function in infants 
with NAS, it could shorten clinical suffering and potentiate long-term behavioral 
outcomes in these infants.  
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Modified Finnegan Neonatal Abstinence Scoring Tool 
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